Virometix, a Zurich, Switzerland-based biotechnology company, closed an extension to its recent financing round.
The terms of the transaction and the names of the backers were not disclosed.
The company will use the funds to further speed up the development of its vaccine candidates for infectious and viral diseases.
Led by Dr. Arin Ghasparian, Chief Executive Officer, and Dr. Armando Zuniga, Chief Scientific Officer, Virometix leverages proprietary Synthetic Virus-Like Particle platform technology to develop new vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases.
Founded in 2009, it is a spin-out company from the University of Zurich.
Virometix had closed the first external financing round in May 2014.
FinSMEs
10/12/2014